Shared Decision Tool for ADPKD Treatment
Part of Genetic & congenital, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study helps people with ADPKD and moderate kidney damage decide together with their doctor whether to start a treatment called tolvaptan. It tests a shared decision-making tool to see if it helps patients understand their options better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 80 years old.
- You have chronic kidney disease (CKD) stage 2 or 3—your kidneys have some damage but are still working fairly well.
- You have autosomal dominant polycystic kidney disease (ADPKD) with a Mayo classification of 1C, 1D, or 1E (a specific pattern seen on scans).
- You can use a computer, tablet, or smartphone to communicate (like reading messages or video chatting).
- You do NOT have serious vision problems or trouble thinking clearly.
- You have NOT taken tolvaptan before for ADPKD, and you are not allergic to it.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This registry study collects information about adults with autosomal dominant polycystic kidney disease (ADPKD) who are starting or already taking tolvaptan. It may help researchers understand how tolvaptan is used in real life and what outcomes look like over time.
This study tests a new investigational drug called GV-100 to see how safe it is and how the body handles it. It is for healthy adults and will be given in different doses to find the best one.
This trial tests a drug (JMKX003142) for people with autosomal dominant polycystic kidney disease that is getting worse quickly. It may help slow down kidney damage.
This trial tests if the cholesterol-lowering drug bempedoic acid can slow kidney function loss in people with autosomal dominant polycystic kidney disease (ADPKD). It may offer a new option to protect your kidneys.
This study tests whether a shared decision-making approach—using decision aids and guided discussions—helps people make better choices for kidney cancer treatment. It may help you feel more informed and involved when you and your care team decide on next steps.
This trial is for children from 28 days old up to 18 years who have a rare kidney disease called ARPKD. It will test if the drug tolvaptan is safe for them. The study helps find new treatment options for kids with this condition.
Hear when a new ADPKD (autosomal Dominant Polycystic Kidney Disease) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.